clinical trial · NCT07111507
A Study of Tarlatamab for People With Prostate Cancer
Metastatic Prostate CancerTarlatamab
brief summary
The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).
started
Jul 31, 2025
primary completion
Aug 31, 2027
completion
Aug 31, 2027
last updated
Jun 17, 2026
official title
TIDAL: Phase 2 Study of Tarlatamab in Patients With Delta-like Protein 3 (DLL3) Positive Metastatic Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol